New vibatv® pediatric publication highlights its safety in patients 2 to 17 years of age

Nashville, tenn. , oct. 10, 2023 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix) announced today a new publication in antimicrobial agents and chemotherapy 1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of vibativ® (telavancin) injection in children 2 to 17 years of age.

CPIX Ratings Summary

CPIX Quant Ranking